The mechanism of action of the factor in leprosy serum that inhibits the growth of mitogen-stimulated normal human lymphocytes.
A factor found in the serum of patients with leprosy that inhibits the growth of mitogen-stimulated normal peripheral blood lymphocytes has been studied. The inhibitor, previously identified as an IgG, has been shown to act by blocking the recruitment of lymphocytes into growth. It was not cytotoxic and did not inhibit the rate of growth of those lymphocytes that had been stimulated. The inhibitory activity was less potent if the serum was added after mitogen stimulation. The inhibitor, which could be absorbed by activated but not resting lymphocyte cultures, appeared to act by inhibition of an early event preceding the release of IL-2. The inhibition of mitogen stimulation was overcome by the addition of purified IL-2, although the inhibitor did not block the action of IL-2 on a long-term cultured IL-2-dependent cell line.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002455:Cell Division; D002648:Child; D005260:Female; D006801:Humans; D007108:Immune Tolerance; D007074:Immunoglobulin G / Q000276:immunology*; D007376:Interleukin-2 / Q000032:analysis / Q000276:immunology; D007918:Leprosy / Q000276:immunology*; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000166:cytology / Q000276:immunology; D008222:Lymphokines / Q000008:administration & dosage / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D010835:Phytohemagglutinins / Q000494:pharmacology; D013601:T-Lymphocytes / Q000166:cytology
D007074:Immunoglobulin G; D007376:Interleukin-2; D008222:Lymphokines; D010835:Phytohemagglutinins